Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study evaluates the effectiveness of low-dose corticosteroids in managing grade 2-3 immune-related hepatitis in cancer patients treated with immune checkpoint inhibitors. It aims to determine whether of 0.5-1miligram per kilogram bodyweight prednisolone is sufficient to manage immune-related hepatitis without the need for dose escalation or additional immunosuppressive therapy.
Epistemonikos ID: e8cedfdaae4ccc2172cc1aa68bd7d2114c4da2f6
First added on: Sep 12, 2025